Serum CK, CK-MB, and cTnI levels of the two groups of patients after treatment were lower than those before treatment, and the observation group was lower than the control group, suggesting that dapagliflozin has a certain protective effect on the heart function of STEMI patients with T2DM and can effectively restore the heart contraction function reduceing myocardial damage [15]. Here, TNNI3 is linked to type 2 diabetes mellitus.